

1 **Evidence for Virus-Mediated Oncogenesis in Bladder Cancers Arising in Solid Organ**
2 **Transplant Recipients**

3
4 **Authors**

5 Gabriel J Starrett¹, Kelly Yu², Yelena Golubeva³, Petra Lenz³, Mary L Piaskowski¹, David Petersen¹,
6 Michael Dean², Ajay Israni⁴, Brenda Y Hernandez⁵, Thomas C Tucker⁶, Iona Cheng⁷, Lou Gonsalves⁸,
7 Cyllene R Morris⁹, Shehnaz K Hussain¹⁰, Charles F Lynch¹¹, Reuben S Harris¹², Ludmila Prokunina-
8 Olsson², Paul Meltzer¹, Christopher B Buck^{1*}, and Eric A Engels^{2*}.

9
10 **Affiliations**

11 ¹ CCR, NCI, NIH, Bethesda, MD, USA

12 ² DCEG, NCI, NIH, Rockville, MD, USA

13 ³ Leidos Biomedical Research Inc., Frederick, MD, USA

14 ⁴ Department of Medicine, Nephrology Division, Hennepin Healthcare System, University of Minnesota-
15 Twin Cities, Minneapolis, MN, USA

16 ⁵ University of Hawai'i Cancer Center, Honolulu HI, USA

17 ⁶ The Kentucky Cancer Registry, University of Kentucky, Markey Cancer Center, KY, USA

18 ⁷ University of California-San Francisco, Department of Epidemiology & Biostatistics, and Helen Diller
19 Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA

20 ⁸ Connecticut Tumor Registry, Connecticut Department of Public Health, Hartford, CT, USA

21 ⁹ California Cancer Reporting and Epidemiologic Surveillance Program, UC Davis Comprehensive
22 Cancer Center/UC Davis Health, Davis, CA, USA

23 ¹⁰ Cedars-Sinai Cancer and Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA,
24 USA

25 ¹¹ The Iowa Cancer Registry, The University of Iowa, Iowa City, IA, USA

26 ¹² Howard Hughes Medical Institute, University of Minnesota-Twin Cities, Minneapolis, MN, USA

27 *These authors contributed equally

28

1 **Corresponding author:** Gabriel J Starrett, gabe.starrett@nih.gov

2

3 **Author Contributions:**

4 GJS, CBB, and EAE interpreted data, conceptualized, and drafted the initial manuscript. GJS performed
5 data analysis, statistics, and generated figures. EAE and KY analyzed and summarized case clinical data.
6 GJS, MLP, and DP extracted nucleic acids and prepared libraries from tumor specimens. MD, PM, LP,
7 and RSH provided key resources and interpreted data. YG performed IHC and PL reviewed and analyzed
8 histology for all specimens. KY, AI, TCT, IC, LG, CRM, CFL, BYH, and SKH coordinated case and
9 specimen identification and acquisition from registry hospitals. All authors read and approved the final
10 manuscript.

11

12 **Competing Interest Statement:** RSH is a co-founder, shareholder, and consultant of ApoGen
13 Biotechnologies Inc. The remaining authors have no competing interests to declare.

14 **Preprint Servers:** MedRXiv, <https://www.medrxiv.org/content/10.1101/2021.11.11.21266080v1>

15 **Keywords:** Bladder cancer, polyomavirus, papillomavirus, torque teno virus, solid organ
16 transplant recipient

17

18 **This PDF file includes:**

19 Main Text, words 7454

20 Figures 1 to 6

21 Tables 1 and 2

22

23

1 **Main Text**

2 **Abstract**

3 A small percentage of bladder cancers in the general population have been found to harbor
4 DNA viruses. In contrast, up to 25% of tumors of solid organ transplant recipients, who are at an
5 increased risk of developing bladder cancer and have overall poorer outcome, harbor BK
6 polyomavirus (BKPyV). To better understand the biology of the tumors and the mechanisms of
7 carcinogenesis from potential oncoviruses, we performed whole genome and transcriptome
8 sequencing on bladder cancer specimens from 43 transplant patients. Nearly half of tumors
9 from this patient population contained viral sequences. The most common were from BKPyV
10 (N=9, 21%), JC polyomavirus (N=7, 16%), carcinogenic human papillomaviruses (N=3, 7%),
11 and torque teno viruses (N=5, 12%). Immunohistochemistry revealed variable Large T antigen
12 expression in BKPyV-positive tumors ranging from 100% positive staining of tumor tissue to less
13 than 1%. In most cases of BKPyV-positive tumors, the viral genome appeared to be clonally
14 integrated into the host chromosome consistent with microhomology-mediated end joining and
15 coincided with focal amplifications of the tumor genome similar to other virus-mediated cancers.
16 Significant changes in host gene expression consistent with the functions of BKPyV Large T
17 antigen were also observed in these tumors. Lastly, we identified four mutation signatures in our
18 cases with those attributable to APOBEC3 and SBS5 being the most abundant. Mutation
19 signatures associated with the antiviral drug, ganciclovir, and aristolochic acid, a nephrotoxic
20 compound found in some herbal medicines, were also observed. The results suggest multiple
21 pathways to carcinogenesis in solid organ transplant recipients with a large fraction being virus-
22 associated.

23

24 **Author Summary**

25 Solid organ transplant recipients are at a significantly increases risk for developing bladder
26 cancer compared to the general population, suggesting a potential infectious origin to these

1 tumors. This study identifies that BK polyomavirus, JC polyomavirus, human papillomaviruses,
2 and anelloviruses are commonly found in bladder tumors of solid organ transplant recipients. In
3 most cases when detected, BK polyomavirus is integrated into the tumor genome and
4 associates with genomic structural changes and distinct gene expression through the activity of
5 viral oncogenes. Additionally, mutational signature analysis suggests that a subset of tumors of
6 solid organ transplant recipients develop through distinct mutagenic processes compared to the
7 general population. Together these results indicate multiple distinct mechanisms of
8 carcinogenesis in bladder cancers of solid organ transplant recipients that may have
9 implications for prevention, treatment, and outcome.

10

11 **Introduction**

12 At least 20% of all cancers are attributable to viral, bacterial, or parasitic infections (1). The
13 advent of high-throughput deep sequencing has provided unprecedented opportunities to learn
14 how infectious agents are involved in cancer in an unbiased manner. Several previous studies
15 have searched for microbial nucleotide sequences in The Cancer Genome Atlas (TCGA), the
16 International Cancer Genome Consortium (ICGC), and PanCancer Analysis of Whole Genomes
17 (PCAWG) datasets (2, 3). In addition to confirming known associations, such as the presence of
18 human papillomaviruses (HPVs) in cervical cancer, these studies also uncovered rare cases in
19 which viral sequences were unexpectedly found in other major cancers affecting the general
20 population (3).

21

22 Despite the immense amount of tumor sequencing data generated to date, the identification of
23 microorganisms in common cancers through these studies has been limited. A more focused
24 assessment of groups at increased risk for virus-associated cancers may be needed. In
25 particular, oncogenic viruses may contribute to a larger fraction of cancer cases among
26 immunosuppressed individuals, such as those with human immunodeficiency virus (HIV)

1 infection and organ transplant recipients. These populations have been previously shown to be
2 at increased risk for developing papillomavirus-mediated cancers, and the oncogenic viruses,
3 KSHV and Merkel cell polyomavirus, were discovered in these patients (4-6).

4
5 Roughly a dozen “high-risk” HPV types cause nearly all cervical cancers, a large majority of
6 other anogenital cancers, and about half of all oropharyngeal cancers (7). The carcinogenic
7 effects of these small circular double-stranded DNA viruses are primarily dependent on
8 expression of the E6 and E7 oncogenes which, among a wide range of other functions,
9 inactivate the tumor suppressor proteins p53 and Rb, respectively (8-12).

10
11 Polyomaviruses share many biological features with papillomaviruses. In particular,
12 polyomavirus T antigens perform many of the same functions as papillomavirus oncoproteins
13 and are similarly oncogenic in cellular and animal models (13). Merkel cell polyomavirus
14 (MCPyV) has been identified as an etiological factor in a rare skin cancer, Merkel cell carcinoma
15 (5, 14, 15). Another human polyomavirus, BK polyomavirus (BKPyV), has a long-debated
16 history as a candidate cancer-causing virus. Several case reports have described the detection
17 of BKPyV in bladder cancers arising in transplant recipients, and kidney recipients who develop
18 BKPyV viremia or BKPyV-induced nephropathy (BKVN) after transplant are at increased risk of
19 bladder cancer (16-19).

20
21 Similar to HPV-induced cervical and oropharyngeal cancers, bladder cancers exhibit somatic
22 point mutations that are largely attributable to the activity of APOBEC3 family cytosine
23 deaminases (20-22). These enzymes normally function as innate immune defenses against
24 viruses by deaminating cytosines in single-stranded DNA, leading to hypermutation of the viral
25 genome (23). Commonly, APOBEC3 enzymes, particularly APOBEC3A and APOBEC3B, can
26 become dysregulated and cause carcinogenic damage to cellular DNA during the development

1 of various types of cancer (24). APOBEC3A and APOBEC3B are upregulated in response to
2 expression of HPV E6 and E7, and APOBEC3A can restrict HPV replication (25-29). The large
3 T antigens (LTAg) of BKPyV and JC polyomavirus (JCPyV, a close relative of BKPyV) also
4 upregulate APOBEC3B expression and activity (30-32).

5
6 To characterize the mutational, transcriptomic, and viral landscapes of bladder cancers arising
7 in immunosuppressed individuals, we evaluated archived tissues from 43 solid organ transplant
8 recipients who developed this malignancy. We performed total RNA sequencing and whole
9 genome sequencing (WGS) from these tissues. We utilized high-sensitivity methods and
10 comprehensive reference sequences for conserved viral proteins to identify known viral species
11 and to search for divergent viruses. Once viruses were identified, we further evaluated the
12 sequence data for integration events, point mutations, mutation signatures, and differentially
13 expressed genes to identify differences correlating with the presence of these viruses and their
14 integration state.

15

16 **Results**

17 *Bladder cancers from transplant recipients*

18 The study population was comprised of 43 U.S. bladder cancer cases from patients who
19 developed cancer after receiving solid organ transplantation (Table 1). Seventy percent were
20 male and 70% non-Hispanic white. The median age at cancer diagnosis was 65 years (range:
21 27-82). The most commonly transplanted organ was the kidney (56%), followed by heart and/or
22 lung (33%) and liver (9%). Primary tumors were roughly an equal mixture of high- and low-grade
23 carcinomas diagnosed a median of 5.7 years after transplantation. Twelve cases were
24 categorized as in situ as defined by the Surveillance, Epidemiology, and End Results (SEER)
25 Program, with two of those cases being transitional cell carcinomas in situ and ten cases being
26 noninvasive papillary transitional cell carcinomas. Invasive cases were mostly categorized into

1 the localized stage (n=20, 46%), which includes tumors that have invaded into the mucosa,
2 submucosa, muscle or subserosa. The eleven remaining cases either had regional or distant
3 invasion or metastasis. We successfully generated WGS data for 39 primary tumors, 3
4 metastases, and 3 normal tissues, with a median of 31x coverage across the human genome
5 (range: 14-55x). We generated total RNA sequencing data for 42 primary tumors, 5 metastases,
6 and 15 normal tissues, with a median of 30 million reads per sample (range: 4-65.5 million).

7

8 *Detection of viruses in bladder cancers from transplant recipients*

9 Analysis of WGS data for 39 primary tumors identified one or more virus species in 16
10 specimens (41%) (Figure 1A). RNA sequencing on tumor samples for which WGS data could
11 not be obtained revealed three additional cases containing viral sequences (45% of samples
12 overall). Among the 20 virus-positive primary tumors, the majority harbored BKPyV (n=9) or
13 JCPyV (n=7). High-risk HPV genotypes 16 and 51 were detected in one and two tumors,
14 respectively. A low-risk papillomavirus, HPV28, was observed in TBC33. One BKPyV-containing
15 tumor (case TBC05) also harbored relatively abundant amounts of HPV20. Only two reads
16 mapped to HPV20 in the RNA dataset for case TBC05. Sequencing of metastases confirmed
17 the presence of BKPyV in TBC06, JCPyV in TBC34, and HPV16 in TBC10. Additionally,
18 sequencing of two separate tumor sections for TBC03 and TBC09 confirmed the presence of
19 BKPyV in both.

20

21 WGS from TBC16, TBC17, TBC18, TBC19, TBC20, TBC21, TBC22, TBC23, TBC24, TBC27
22 had low numbers of reads mapping to the BKPyV genome that were judged to be attributable to
23 low levels of index-hopping from TBC01, a papillary urothelial neoplasm of low malignant
24 potential (PUNLMP) that had extremely high BKPyV coverage and was sequenced in the same
25 run. Considering this, along with the absence of RNA reads supporting the presence of BKPyV,
26 we scored these tumors virus-negative.

1
2 A separate set of searches aimed at identifying divergent members of other virus groups
3 revealed that several tumors (TBC08, TBC14, TBC25, TBC28, and TBC35) and normal tissues
4 (TBC35, TBC28, TBC39) harbored torque teno virus (TTV) sequences from either WGS or RNA
5 sequencing (Supplemental Table S3). Epstein Barr virus was most strongly detected in one
6 normal lymph node (TBC23) and, at low levels, in tumors TBC07 and TBC08. Considering the
7 stronger epidemiological evidence for BKPyV and bladder cancer and its abundance in these
8 specimens, we focused the majority of our analysis on characterizing these tumors.

9 10 *Features of BKPyV-positive tumors*

11 BKPyV sequences detected in this study came from every genotype except IV (Figure 2A). One
12 patient with a BKPyV-positive tumor had a documented history of BKVN. We identified
13 unambiguous BKPyV integration sites in five of the nine BKPyV-positive tumors and in one
14 normal tissue (Figure 2B & Table 2). For three tumors a single integration junction was
15 identified, and in TBC02 three junctions were identified. In case TBC03, two separate sections
16 from separate blocks of the primary tumor were sequenced. In one of the two sections, 11
17 integration junctions were identified across seven chromosomes. Only three of the junctions
18 could be identified in the second section of the tumor, suggesting either that these junctions
19 were not present throughout the tumor or there was insufficient tumor purity/sequencing depth
20 to detect them.

21
22 Integration appeared consistent with a microhomology-mediated end-joining (MMEJ) model for
23 integration, as 20 of 25 junctions (80%) had microhomology greater than or equal to 2 bp. In this
24 model, which has previously been proposed for both HPV- and MCPyV-associated tumors (33-
25 35), microhomologies between the virus and host genomes initiate DNA repair processes that
26 can, in some cases, lead to tandem head-to-tail concatemeric repeats of the viral genome as

1 well as focal amplifications of the flanking host chromosome. Consistent with this model, focal
2 amplifications adjacent to BKPyV integration sites were identified in three patient tumors. In
3 TBC03, amplification of a 17 kb region of chromosome 1 flanking a multi-copy BKPyV integrant
4 was observed in two tumor sections (Figure 2C). In TBC04, a 15 kb single-copy amplification of
5 chromosome 3 was identified. Lastly, a 195 kb region of chromosome 6 was amplified next to
6 the BKPyV integration junction in TBC08. Twenty-two of the identified 25 junctions (88%)
7 intersected protein coding genes and thus might conceivably affect gene expression or function.
8
9 BKPyV RNA and DNA abundance by sequencing generally did not correspond to specimen
10 tumor purity or the percentage of LTA_g⁺ cells (Figure 3A and B). Gene level analysis of the
11 RNA sequencing data revealed that nearly all polyomavirus-positive tumors predominantly
12 expressed the T antigens, with little to no expression of the late genes VP1 and VP2 (encoding
13 the major and minor capsid proteins, respectively) (Figure 3A and C, Supplemental Figure S1).
14 The LTA_g open reading frames (ORFs) in these cases were truncated before the helicase
15 domain through deletions, frameshifts, or point mutations. An exception was the BKPyV-positive
16 PUNLMP case TBC01, which showed balanced expression of both early and late regions.
17
18 BKPyV isolates found in cases of polyomavirus nephropathy typically have rearrangements in
19 the regulatory region that enhance viral replication in cell culture. However, in this study, TBC01
20 was the only polyomavirus-positive tumor showing evidence of regulatory region
21 rearrangements (Supplemental Figure S1).
22
23 Immunohistochemistry (IHC) for polyomavirus LTA_g was performed on 18 specimens suspected
24 to contain polyomaviruses and two negative control specimens determined to be free of
25 detectable viral sequences. Control sections were negative for TAg staining, whereas 11 of the
26 18 specimens that contained polyomavirus sequences showed at least some evidence for TAg

1 positivity (Figure 3B and Supplemental Figure S1). Three tumors scored as BKPyV sequence-
2 positive had strong to moderate LTA_g staining in greater than 80% of tumor cells, but the other
3 BKPyV-positive tumors had more variable staining. Moderate to weak staining was visible in
4 less than 0.5% cells in the primary tumor for TBC06 (Figure 3D), but strong staining was
5 observed in about 25% of cells in the metastasis. For TBC09, one sample of the tumor was
6 >90% positive for LTA_g staining and another sample was less than 25% positive (Supplemental
7 Figure S1). The normal tissue for TBC09 showed BKPyV RNA and DNA coverage along a small
8 portion of the regulatory region and small T antigen, but no staining for LTA_g. Although TBC01
9 had very high levels of BKPyV DNA and RNA reads, it had the lowest observed proportion of
10 LTA_g-positive cells (<1% in a section that was >95% tumor). LTA_g-positive cells in the TBC01
11 sample were almost entirely localized to the luminal margin of the tumor (Figure 3D).

12
13 Differential gene expression analysis for BKPyV-positive tumors versus virus-negative tumors
14 revealed 1062 genes that were significantly differentially regulated in tumors harboring BKPyV
15 (Figure 4A, Supplementary Table S4). Clustering all primary and metastatic tumors by genes
16 with a greater than three-fold difference of expression in the above comparison, we identified
17 three major groups that loosely correspond to the amount of BKPyV DNA and RNA in a tumor
18 (Figure 4C). A notable exception is the BKPyV-positive tumor TBC01, which falls into the cluster
19 mostly containing virus-negative tumors.

20
21 The cluster exclusively containing tumors harboring integrated BKPyV is defined by high
22 expression of genes involved in DNA damage responses, cell cycle progression, angiogenesis,
23 chromatin organization, mitotic spindle assembly and chromosome condensation/separation as
24 well as some genes associated with neuronal differentiation. Overall, these tumors have
25 relatively low expression of keratins and genes associated with cell adhesion. Genes previously
26 shown to be associated with cell proliferation in bladder cancer, such as FGFR3, had

1 significantly lower expression in BKPyV-positive tumors relative to virus-negative tumors.
2 Notably, tumors harboring BKPyV had significantly higher average *APOBEC3B* expression
3 compared to both normal tissues and tumors not containing any virus (Figure 4B). This
4 observation is maintained after stratifying the cases by the germline variant, rs1014971, known
5 to associate with increased *APOBEC3B* expression and bladder cancer risk with highest
6 average *APOBEC3B* expression observed in tumors with both BKPyV and two copies of
7 rs1014971 (Supplemental Figure S2).

8
9 In TBC03, the observed BKPyV integration into Breast Cancer Antiestrogen Resistance 3
10 (BCAR3) results in increased expression of the host gene. Further evaluation of RNA reads
11 covering this region revealed a general enrichment of sense and antisense reads mapping to
12 positions 93,688,393-93,704,476, corresponding to the amplified chromosomal region observed
13 in the WGS dataset. There is an even greater enrichment of mapped reads between positions
14 93,694,469-93,696,857. No increases in expression in nearby host genes were observed for
15 other cases and integration events.

16
17 Aside from integration related copy number changes (CNVs), large scale CNVs overall differed
18 between BKPyV-positive and virus-negative tumors (Figure 5, Supplementary Table S6).
19 BKPyV-positive tumors showed moderate enrichments for gains of chromosome segments 1q,
20 2p, 3p, 7q, 20q and 22q, while losses of chromosome 2q, 6q, and 10q were also observed more
21 frequently in BKPyV-positive tumors versus virus-negative tumors. Similar differences in copy
22 numbers have been observed for virus-positive and virus-negative Merkel cell carcinoma (33).

23
24 *Features of other virus-positive tumors*

25 In the cases that were positive for JCPyV, DNA and RNA coverage depth was much lower than
26 observed for BKPyV-positive tumors, and in several DNA-positive cases JCPyV transcription

1 was not detected (Figure 1). JCPyV reads were detected in three samples from case TBC12
2 including the primary tumor, tumor-positive lymph node, and adjacent normal bladder wall
3 (Supplemental Figure S3). IHC detected sparse LTA_g staining in JCPyV-positive case TBC13,
4 but not in any tissue samples for TBC12.

5
6 For two of three cases harboring HPV types known to cause cervical cancer (HPV16 and
7 HPV51), transcripts encoding the E6 and E7 oncogenes were detected (Supplemental Figure
8 S4). In one HPV16+ case (TBC10), viral oncogene RNA expression was detected in both the
9 primary and metastatic specimens. A possible HPV51 integration event in TBC32 appears to
10 have involved a Mer4-int retrotransposon. Lastly, one case harbored DNA sequences aligning
11 to HPV20 and a single case harbored DNA aligning to HPV28; however, no RNA reads were
12 detected for these cutaneous HPV types (Supplemental Figure S4).

13
14 For the five TTV-positive tumors, the WGS analyses did not show evidence of integration.
15 However, we were unable to assemble complete circular genomes for any of the TTVs. The
16 missing segments all overlapped the GC-rich origin of replication that forms stable hairpins and
17 is therefore relatively resistant to sequencing with standard Illumina technology (36). All
18 observed TTV ORF1 sequences belonged to the *Alphatorquevirus* genus and had 51-100%
19 amino acid identity to previously reported TTV strains (Supplemental Table S3).

20
21 *Mutation signature analysis*

22 The overall tumor mutation burden, as measured by non-synonymous mutations per million
23 bases, did not show a clear correlation with the presence of viral sequences (Figure 6A). We
24 analyzed likely somatic point mutations from all tumors and deconvoluted mutation signatures
25 (Figures 6B and 6C, Supplemental Figure S5). As expected for bladder cancer, we commonly
26 observed single-base substitution 2 (SBS2) and SBS13 (both characteristic of APOBEC3

1 mutagenesis, N=13 cases) and SBS5 (associated with smoking history and ERCC2 mutations,
2 N=11 cases).

3
4 Four tumors (TBC16, TBC28, TBC31, TBC33) carried a predominant SBS22 signature, which is
5 caused by the chemical aristolochic acid found in the birthwort family of plants. Cases with this
6 signature showed a very high mutational burden (Figure 6A). In support of the idea that cases
7 with strong SBS22 signatures arose through environmental exposure, one such case, a kidney
8 recipient, was previously diagnosed with Chinese herbal medicine nephropathy. The final
9 deconvoluted signature closely matched the mutation spectrum caused by the deoxy-guanosine
10 analog, ganciclovir, recently identified in hematopoietic stem cell transplant recipients (Figure
11 6B) (37).

12

13 *Recurrent somatic mutations*

14 Numerous cellular genes were found to recurrently harbor nonsynonymous, nonsense, and
15 frameshift mutations (Figure 6E). The spectrum of frequently mutated genes is similar to those
16 reported in various types of urothelial carcinoma (e.g., mutations in *KMT2D*, *KDM6A*, and
17 *ARID1A*) (Supplemental Table S5)(20, 38, 39). No nonsynonymous mutations were identified in
18 *FGFR3* or *PIK3CA*, even though these genes are commonly mutated in non-muscle invasive
19 bladder cancer (NMIBC) (40). Mutations in *TP53*, which are common in muscle-invasive bladder
20 cancer (20), were detected in four tumors (Figure 6E).

21

22 To address the reproducibility of mutation calls in deep sequencing of FFPE samples, we
23 analyzed the sequences from two independent sections from separate blocks for three tumors
24 (Figure 6D). Comparing the variants called in these tumors, 77-82% of inferred somatic
25 mutations were common to both sections. Furthermore, a similar comparison showed a large
26 percentage of variants in common between primary tumors and their metastases (Figure 6D). In

1 TBC06, 84% of the likely somatic mutations in the metastasis were found in the primary tumor,
2 whereas only 28% of the likely somatic variants in the primary tumor were found in the
3 metastasis. In an additional primary-metastatic pair (TBC34), we identified a similar proportion
4 of shared “trunk” mutations but the metastasis had more unique, likely somatic variants.

5

6 **Discussion**

7 This report presents a comprehensive molecular assessment of 43 bladder cancers arising in
8 solid organ transplant recipients by WGS and total RNA sequencing. DNA and/or RNA
9 sequences of human BK or JC polyomaviruses were detected in 16 tumors (37%). Expression
10 of the polyomavirus LTA_g was documented immunohistochemically in ten cases. HPV
11 sequences were detected in six cases, including four cases with HPV types known to cause
12 cervical cancer. Overall, this is a much higher frequency of small DNA tumor virus sequence
13 detection compared to prior surveys of bladder cancers affecting the general population, where
14 fewer than 5% of tumors harbor small DNA tumor virus sequences (3, 41). The results suggest
15 that human polyomaviruses and papillomaviruses can play a carcinogenic role in the
16 development of bladder cancer, particularly among transplant recipients.

17 BKP_g infection in organotypic urothelial cell culture has been shown to promote cellular
18 proliferation, consistent with the known transforming effects of its T antigens (42). Interestingly,
19 we observed frequent clonal loss of the p53-inactivating helicase domain of BKP_g LTA_g due to
20 deletions and point mutations in the integrated virus. While such deletions in LTA_g are
21 commonly observed in MCP_g-positive Merkel cell carcinoma (14), MCP_g LTA_g lacks the p53-
22 inactivating activity of the C-terminal helicase domain of BKP_g. One might thus have expected
23 the C-terminal portion of BKP_g LTA_g to be preserved in tumor cells. We speculate that the loss
24 of the BKP_g helicase domain is driven by negative selection against deleterious effects of
25 LTA_g on tumor survival (e.g., LTA_g might unwind the integrated BKP_g origin of replication and
26 initiate “onion skin” DNA structures leading to chromosomal instability and cell death). The

1 absence of the p53-binding domain may be compensated for in some BKPyV-positive tumors
2 through the significantly increased expression of the ubiquitin ligase TRIM71 that we observed.
3 TRIM71 has been shown to bind and poly-ubiquitinate p53 for proteasomal degradation and
4 prevent apoptosis during stem cell differentiation (43).

5 We also observed amplification of the host genome surrounding BKPyV integration sites,
6 consistent with circular DNA intermediates and/or MMEJ break-induced replication. Similar
7 findings have been reported for HPV and MCPyV-associated tumors (33, 44). These
8 amplification events result in a variable number of tandem head-to-tail copies of the virus and
9 host genome that are thought to create super-enhancers affecting viral and host gene
10 expression (45, 46). In cervical cancer, frequently only one integration event is transcriptionally
11 active; however, in tumors carrying integrated BKPyV sequences, the abundance of viral DNA
12 and RNA are positively correlated, suggesting that each integrated copy produces viral
13 transcripts. While the observed integration sites in this study are unique and have not been
14 observed in Merkel cell carcinoma, HPV16 integration has been reported previously in BCAR3
15 (47). Elevated expression of BCAR3 has been shown to increase proliferation, motility, and
16 invasiveness of estrogen receptor-positive breast cancer cells after treatment with antiestrogens
17 (48, 49).

18 In five tumors harboring integrated BKPyV sequences (TBC02, TBC03, TBC05, TBC06
19 and TBC08), we observed significant upregulation of genes associated with cell cycle
20 progression, DNA damage, histones, and the mitotic spindle. Tumors with evidence of BKPyV
21 integration also exhibited significant downregulation of keratins and cell adhesion genes. The
22 latter may contribute to the high grade and invasive behavior of BKPyV-positive tumors
23 observed in this study and others (50-54).

24 Many of the observed gene expression changes are consistent with known effects of
25 BKPyV infection and the specific activities of LTA_g, which binds Rb-family proteins and alters
26 the active pool of E2F transcription factors in the cell (55, 56). Recent studies have shown that

1 APOBEC3B expression is repressed by the DREAM complex (which is composed of Rb-family
2 proteins and E2F transcription factors (30)) and, accordingly, we found that APOBEC3B is more
3 highly expressed in BKPyV-positive tumors compared to normal tissues and tumors without
4 tumor virus sequences likely due to LTA_g activity. However, despite this increased expression,
5 the mutation signature commonly attributed to APOBEC3B did not appear enriched in BKPyV-
6 positive tumors versus other tumors. It is possible that tumors expressing BKPyV LTA_g and
7 increased APOBEC3B manifested greater intratumor heterogeneity, but we were unable to
8 detect possible low frequency APOBEC3-mediated variants from FFPE tissue without deeper
9 and more accurate sequencing. Additionally, consistent with the disruption of the DREAM
10 complex in these tumors, we observed higher expression of MYBL2, a key component of the
11 MMB complex, and one of its targets, FOXM1, which regulates numerous genes required for
12 G2/M progression. We also observed increased expression of FOXM1 downstream targets
13 associated with the centromere and kinetochore, which have been shown to promote improper
14 chromosome segregation and tumorigenesis (57-59).

15 BKPyV-positive tumors in our study had significantly higher expression of a number of
16 genes that promote homologous recombination (e.g. RAD51, RAD54L, BRCA1, and BRCA2)
17 and protect against replication fork stalling and collapse (e.g. RAD51, XRCC2, and FANCB)
18 relative to virus-negative tumors (60). Claspin (CLSPN) and TIMELESS, which interact with
19 replicative polymerases and helicases are also highly expressed in BKPyV-positive tumors,
20 further promoting replication fork progression and genome stability (61). This expression pattern
21 might promote cell survival in the face of genomic damage caused by viral genome integration,
22 oncogene expression, and APOBEC3B upregulation.

23 While HPVs are not generally considered causative agents of bladder cancer, they have
24 been detected in rare cases of bladder cancer affecting immunocompetent and
25 immunosuppressed patients (2, 3, 62). In the current study, we identified four tumors with
26 carcinogenic *Alphapapillomavirus* sequences (HPV16 or HPV51). *Alphapapillomaviruses* are

1 believed to cause cancer through sustained expression of their E6 and E7 oncoproteins, which
2 is frequently associated with integration of the papillomavirus genome into the tumor genome.

3 One case in the panel carried sequences of HPV20, a *Betapapillomavirus* that can
4 cause cutaneous squamous cell carcinoma in animal model systems (63). The possible
5 involvement of *Betapapillomaviruses* in skin cancer in the general population remains
6 controversial (64). In epidermodysplasia verruciformis, a rare syndrome caused by defects in
7 zinc-binding proteins EVER1 and EVER2, patients frequently develop non-melanoma skin
8 cancers containing *Betapapillomaviruses* (65). Expression of E6 and E7 from
9 *Betapapillomaviruses* has been shown to promote cell survival in the face of ultraviolet radiation
10 damage and other carcinogenic insults (63, 64, 66). In the context of bladder cancer, it is
11 possible that cutaneous papillomaviruses likewise enable the accumulation of carcinogenic DNA
12 damage. Additionally, identification of HPV28, an *Alphapapillomavirus* that is not generally
13 associated with cervical cancer, suggests more abundant papillomavirus infections of the
14 bladder than previously assumed, with unknown implications for carcinogenesis.

15 An explanation for the observation that viruses are more prevalent in bladder cancers
16 affecting solid organ transplant recipients compared to cases in the general population is that, in
17 combination with immune suppression, transplant recipients may often become newly infected
18 through transmission from the donor graft at the time of transplantation, perhaps with a different
19 viral genotype than present in the host previously. This phenomenon is commonly observed in
20 kidney transplantation and is associated with BKVN (67), but has not been documented for
21 heart, lung, or liver transplant recipients, who are also included in the current study. The lack of
22 detection of BKPyV genotype IV in this study may indicate that this genotype represents a less
23 carcinogenic strain, reminiscent of “low risk” HPV types that are rarely found in tumors.
24 Additionally, this study and one prior study (68) identified JCPyV in bladder tumors. Based on
25 the high degree of similarity between JCPyV and BKPyV, it seems reasonable to expect that the
26 two species would behave similarly. However, the low abundance of JCPyV RNA and DNA in

1 these specimens and absence of integration, together with the ubiquity of latent JCPyV
2 infections in the urinary tract, raises the possibility that these observations reflect incidental
3 detection events.

4 The data from this study and others suggest that in the context of strong immune
5 suppression BKPyV can cause bladder cancer through clonal integration but is rarely detected
6 in tumors of the general population. While most adults are seropositive for BKPyV with at least
7 10% having detectable BKPyV in the urine, BKPyV is only observed in upwards of 4% of
8 NMIBC cases and less than 0.25% in muscle-invasive bladder cancers in the general population
9 (3, 41). This implies that, while BKPyV LTA_g can provide a growth advantage to cells in culture,
10 the large multi-domain antigen may be relatively immunogenic compared to the much smaller
11 oncoproteins encoded by high-risk HPVs or the highly truncated MCPyV LTA_g isoforms typically
12 observed in tumors. Immunologic recognition of these tumors may also be impacted by the
13 increased expression of APOBEC3B, which can generate immunogenic neoantigens (69, 70).
14 Several reports of regression of patients' BKPyV-positive tumors after reduction of immune
15 suppression support the idea that tumors constitutively expressing BKPyV gene products are
16 readily targeted and controlled by the immune system (71-73). The theoretical immunological
17 costs of viral gene expression for a nascent tumor cell raise the possibility of "hit-and-run"
18 carcinogenesis. The hit-and-run hypothesis invokes the idea that a virus may play a causal role
19 in early stages of carcinogenesis but then become undetectable at more advanced stages of
20 tumor development. Infection of a premalignant cell may promote its growth and survival
21 through the expression of the viral oncogenes. Additionally, expression of viral oncogenes may
22 also promote genome instability through the expression of the mutagenic APOBEC3 enzymes
23 or other mechanisms that further push the cell towards transformation as has been suggested
24 by a recent study of BKPyV infection in differentiated urothelium (74).

25 The heterogeneous expression of LTA_g observed in this study could represent
26 transcriptional silencing or loss of BKPyV DNA from one part of the tumor, supporting the idea

1 that tumors can lose the need for LTA_g expression. Alternatively, our observations could be
2 accounted for by a multistage integration and carcinogenesis process proposed by other recent
3 studies on BKPyV-positive urinary tumors from kidney transplant recipients (75, 76). However,
4 our sequencing experiments support a dominant clonally integrated form likely established early
5 during tumor development in most BKPyV-positive tumors in this study. The only exception to
6 this observation is TBC01, which appears to exhibit a viable BKPyV episome with a rearranged
7 regulatory region present in a small subset of tumor cells. This also suggests that archetypal
8 BKPyV, rather than the more pathogenic rearranged strains found in cases of nephropathy, is
9 more likely to integrate and be preserved into nascent tumor cells. In support of the idea that
10 integration may be a common aspect of BKPyV infection, we identified a clonal BKPyV integrant
11 in the normal bladder specimen from case TBC09 in both the RNA and WGS sequencing that
12 was distinct from the BKPyV integrant observed in the tumor sample. The normal tissue
13 integrant had multiple copies of small T antigen and a large deletion in the regulatory regions
14 (Supplemental Figure S1). Only a few reads from RNA sequencing mapped to the small T
15 antigen region, and histology of the section indicates no tumor cells or LTA_g staining,
16 suggesting that the virus did not integrate in the right genomic location or maintain the needed
17 components to drive carcinogenesis.

18 It remains to be seen whether TTVs contribute to disease in the context of immune
19 suppression. A general model is that these ubiquitous viruses establish a chronic infection that
20 the immune system generally keeps in check, but immune suppression results in increases not
21 only in the abundance but also the diversity of TTVs observed in hosts (77). Indeed, detection of
22 TTVs can serve as an indicator of the degree of overall immune suppression in transplant
23 recipients (78). Interestingly, these viruses, like papillomaviruses and polyomaviruses, also
24 appear to be depleted for APOBEC3 target motifs, consistent with the effects of an evolutionary
25 virus-host arms race (23, 32, 79).

1 Until recently, this type of molecular assessment from FFPE tissues would have been
2 nearly impossible or badly muddled by the highly damaging effects of formalin fixation and
3 oxidation of nucleic acids over time. Recent advancements in the isolation of nucleic acids, such
4 as low temperature and organic solvent-free deparaffinization, combined with efficient library
5 preparation from low-concentration highly degraded sources, yielded sufficiently high-quality
6 material for WGS variant calling and total RNA sequencing (80). To address the difficulty of
7 accurately calling somatic variants (which can be problematic even from flash frozen or fresh
8 tissues), we called variants using the consensus of three modern variant callers. The lack of
9 matched normal tissues for most cases is a limitation of this work, but our analytical approach
10 accounted for this by focusing the analysis on mutations with >10% allele frequency and those
11 with potential functional effects, and by excluding known germline variants. Our methods were
12 validated internally through the sequencing of separate regions from the same tumor and of
13 primary-metastatic pairs, which reveal similar concordance of mutations as has been reported
14 from flash frozen tissues (81). Our variant calling approach was also validated by the
15 observation that we detected four deconvoluted mutation signatures that match those expected
16 from prior surveys of bladder cancer. However, the low overall coverage of our WGS remains a
17 limitation of this study.

18 We identified four bladder cancers in kidney transplant recipients that exhibited
19 abundant mutations attributable to aristolochic acid-mediated DNA adducts. Aristolochic acid is
20 a highly nephrotoxic and mutagenic compound produced by birthwort plants, which sometimes
21 contaminate certain types of herbal medicines and grains (82). Exposure to this compound likely
22 contributed to the patients' need for kidney transplantation, as well as their eventual
23 development of bladder cancer. Highlighting the highly mutagenic nature of this compound, the
24 four cases with dominant aristolochic acid signature were in the top seven for total mutation
25 burden (Figure 6). None of the three tumors had detectable oncogenic viral sequences, but one
26 had detectable TTV. We also identified likely ganciclovir-mediated mutations (37) in most

1 patients indicating that this common treatment to prevent reactivation of cytomegalovirus in solid
2 organ transplant recipients may promote mutagenesis in the urinary bladder. Unfortunately,
3 ganciclovir treatment history was unavailable for these cases to confirm that this is the origin of
4 this mutation signature in these cases. Ever-decreasing sequencing costs will facilitate
5 additional studies of this type and shed light on rare and understudied tumor types, as well as
6 analyses of lower-grade and pre-cancerous lesions.

7

8 **Materials and Methods**

9 *Sample acquisition and ethics*

10 The Transplant Cancer Match (TCM) Study is a linkage of the US national solid organ transplant
11 registry with multiple central cancer registries (<https://transplantmatch.cancer.gov/>). We used
12 data from this linkage to identify cases of in situ or invasive bladder cancer diagnosed among
13 transplant recipients. Staff at five participating cancer registries (California, Connecticut, Hawaii,
14 Iowa, Kentucky) worked with hospitals in their catchment areas to retrieve archived pathology
15 materials for selected cases.

16

17 We obtained twenty 10-micron sections from formal-fixed paraffin-embedded (FFPE) blocks for
18 cases with available material. At each originating institution, the microtome blade was cleaned
19 with nuclease-free water and ethanol between samples. Single 5-micron sections leading and
20 trailing the twenty sections used for nucleic acid isolation were saved for histochemistry.

21

22 The TCM Study is considered non-human subjects research at the National Institutes of Health
23 because researchers do not receive identifying information on patients, and the present project
24 utilizes materials collected previously for clinical purposes. The TCM Study was reviewed, as
25 required, by human subjects committees at participating cancer registries.

26

1 *Nucleic acid isolation*

2 Samples were simultaneously deparaffinized and digested using 400 μ L molecular-grade
3 mineral oil (Millipore-Sigma) and 255 μ L Buffer ATL (Qiagen) supplemented with 45 μ L of
4 proteinase K (Qiagen). Samples were incubated overnight at 65°C in a shaking heat block.
5 Samples were spun at 16,000 x g in a tabletop microcentrifuge for one minute to separate the
6 organic and aqueous phases. Depending on the presence of visible remaining tissue, some
7 samples were subjected to one or two additional two-hour long digests by the addition of 25 μ L
8 of fresh proteinase K buffer. Lysates were stored at 4°C until RNA or DNA isolation.

9
10 Lysates were spun at 16,000 x g in a tabletop microcentrifuge for one minute. For DNA
11 isolation, 150 μ L of supernatant was moved to a new 1.5 mL tube. 490 μ L of binding buffer PM
12 (Qiagen) and 10 μ L of 3M sodium acetate were added to the lysate. The mixture was then
13 added to a Qiaquick spin column and spun at 16,000 x g for 30 seconds. Flow-through was
14 reapplied to the spin column for complete binding. The column was washed first with 750 μ L of
15 Buffer PE (Qiagen) and then 750 μ L of 80% ethanol, spinning at 16,000 x g for 30 seconds and
16 discarding flow-through each time. The column was dried by spinning it at 16,000 x g for 5
17 minutes. Collection tubes were discarded, and the column was moved to a new microcentrifuge
18 tube. 50 μ L of pre-warmed, 65°C 10% buffer EB was applied to the column and incubated for 1
19 minute. The tube was then spun at 16,000 x g for 2 minutes. DNA quantity and quality were
20 assessed by Qubit (Thermo Fisher) and spectrophotometry (DeNovix). DNA was stored at -
21 20°C until used for library preparation. Only samples with greater than 50ng of DNA were
22 processed for library prep.

23
24 For RNA isolation, 150 μ L of the remaining clarified lysate was moved to a new tube. 250 μ L of
25 buffer PKD (Qiagen) was added and vortexed to mix. The remainder of the RNA extraction
26 process was carried out using a RNeasy FFPE Kit (Qiagen) according to the manufacturer's

1 protocol. RNA quantity and quality were assessed by spectrophotometry (DeNovix) and
2 TapeStation (Agilent).

3

4 *Immunohistochemistry*

5 FFPE 5- μ m thick tissue sections mounted on charged glass slides were stained with antibody
6 against Large T Antigen, clone PAb416 (Sigma Millipore, cat. DP02) which detects LTA_g from
7 multiple polyomaviruses. Slides were baked in a laboratory oven at 60°C for 1 hour prior to
8 immunostaining on Ventana Discovery Ultra automated IHC stainer upon following conditions:
9 CC2 (pH9) antigen retrieval for 64 min at 96°C, antibody at concentration 0.5 μ g/ml in Agilent
10 antibody diluent (cat. S3022) for 32 min at 36°C, Anti-Mouse HQ-Anti HQ HRP detection
11 system for 12 min with DAB for 4 minutes and Hematoxylin II counterstain for 8 minutes. After
12 washing per manufacturer's instructions, slides were incubated in tap water for 10 min,
13 dehydrated in ethanol, cleared in xylene, coverslipped with Micromount media (Leica
14 Biosystems) and scanned on AT2 slide scanner (Leica Biosystems) for pathology review. FFPE
15 sections of cell pellets transfected with LTA_g and commercial slides of SV40 infected tissue
16 (Sigma, cat. 351S) were used as positive controls.

17

18 *Library preparation and sequencing*

19 50-250 ng of isolated DNA was fragmented in microtube-50 using a Covaris sonicator with the
20 following settings: peak power: 100, duty factor: 30, cycles/burst: 1000, time: 108 seconds. End-
21 repair and A-tailing were performed on fragmented DNA using the KAPA HyperPrep Kit
22 (Roche). NEB/Illumina adaptors were ligated onto fragments with KAPA T4 DNA Ligase for 2
23 hours at 20°C then treated with 4 μ L USER enzyme (NEB) for 15 minutes at 37°C to digest
24 uracil-containing fragments. Ligation reactions were cleaned up using 0.8x AMPure XP beads
25 using the KAPA protocol. NEB dual-index oligos were added to the adaptor-ligated fragments
26 and amplified for 6-8 cycles (depending on the amount of input fragmented DNA) using KAPA

1 HiFi HotStart ReadyMix (Roche). Final amplified libraries were cleaned using 1x AMPure beads
2 with the recommended KAPA protocol. Ribosomal sequence-depleted cDNA libraries were
3 prepared using 50 ng of total RNA with the SMARTer Stranded Total RNA-Seq Kit v2 – Pico
4 Input Mammalian (Takara) following the manufacturer instructions for FFPE tissues. Final RNA
5 and DNA libraries were assessed for size and quantity by Agilent TapeStation. Only samples
6 that yielded libraries greater than 5 nM were sequenced.

7
8 DNA libraries were sequenced on the Illumina NovaSeq 6000 at the Center for Cancer
9 Research (CCR) Sequencing Facility. RNA libraries were sequenced on the Illumina NovaSeq
10 6000 and NextSeq 550 in high output mode at the CCR Genomics Core. Sequencing metrics
11 are reported in Supplemental Table S1.

12 13 *Sequence alignments*

14 Reads were trimmed using Trim Galore 0.6.0 with default settings. RNA reads were initially
15 aligned using STAR aligner 2.5.3ab (83) against a fusion reference human genome containing
16 hg38, all human viruses represented in RefSeq as of December 2018 (Supplemental Table S2),
17 and all papillomavirus genomes from PaVE <https://pave.niaid.nih.gov> (84). Default parameters
18 were used with the following exceptions: chimSegmentMin=50, outFilterMultimapNmax=1200,
19 outFilterMismatchNmax=30, outFilterMismatchNoverLmax=1. Any reads that had less than 30
20 bp of perfect identity were excluded. Trimmed DNA reads were aligned with Bowtie2 (2.3.4.3)
21 using the --very-sensitive setting to the same reference genome as mentioned above excluding
22 RNA viruses (85). Alignments were sorted and duplicate sequences were flagged using Picard
23 2.20.5. Indel realignments and base quality recalculations were conducted using GATK.

24 25 *Virus detection and integration analysis*

1 All WGS reads not mapping to the human genome were *de novo* assembled using MEGAHIT
2 (1.1.4) with default parameters (86). All trimmed RNA reads were assembled using
3 RNASPADES (87). Assembled contigs were annotated using BLASTn and BLASTx against the
4 NCBI nt database (October 2021) for closely related species, and CenoteTaker2
5 (<https://github.com/mtisza1/Cenote-Taker2>) was used to identify more divergent species in
6 contigs ≥ 1000 bp (88). Depth and breadth of coverage of viral species were normalized by total
7 number of human reads and length of the viral genome. Only species with $\geq 10\%$ genome
8 coverage and a normalized depth ≥ 10 for a viral genome in a given sample were considered as
9 hits. Viral read k-mers were cross-compared against samples for uniqueness to identify index
10 hopping or potential contamination between samples. Rearrangements in the BKPyV regulatory
11 region were analyzed and annotated using BKTyper (89).
12
13 Bam alignments were input into Oncovirus Tools (github.com/gstarrett/oncovirus_tools) to call
14 integration sites (33, 90). It starts by extracting discordant read pairs (where one read aligns to a
15 sequence of interest, i.e. virus, and the mated read aligns to the human genome) and any
16 remaining reads aligned to the human genome that contain at least one 25bp k-mer from the
17 input sequences of interest as determined by a Bloom filter. It uses the human genomic
18 coordinates from the above reads to identify putative integration regions by merging their
19 stranded mapping positions to find overlaps, counting the number of reads per stranded region.
20 Oncovirus Tools then assembles the extracted reads, together with all unaligned reads, using
21 Spades (91). The resulting assembly graphs are annotated with the human and viral genomes
22 using BLASTn and the annotated assembly graphs are plotted using the R package ggraph.
23 The output is then screened for contigs containing both human and viral hits with BLASTn e-
24 values below $1e-10$. Based on these hits, integration junctions are called and overlaps in host-
25 virus hits on the contigs are then screened for microhomology. All putative integration sites from
26 Oncovirus Tools were manually validated by returning to the original alignment file.

1

2 *Transcriptome clustering and differential gene expression analysis*

3 Counts from STAR were input into R and normalized using the DESeq2 vst function (92). The
4 DESeq2 model was built using the following factor: tissue type (normal, primary, metastasis),
5 grade, stage, and virus status to evaluate their effects on gene expression. Since the RNA seq
6 libraries were prepared in different batches on different days and in different sequencing runs,
7 batch effects were removed using the R package limma and the function RemoveBatchEffects.
8 These normalized counts were input into the R package ConsensusClusterPlus. Pathway
9 analysis was conducted using Enrichr (<https://amp.pharm.mssm.edu/Enrichr>) (93, 94).

10

11 *Somatic point mutation, structural variant, and copy number variant calling*

12 Point mutations were called using Mutect2, VarScan2 and lofreq with default parameters (95,
13 96). Consensus calls between these variant callers were performed using SomaticSeq (3.3.0)
14 (97). Likely germline variants were annotated and removed using SnpSift and dbSNP v152.
15 Likely somatic point mutations were further filtered by the following criteria: SomaticSeq PASS
16 filter, $\geq 10\%$ allele frequency, ≥ 4 reads supporting the variant allele, and ≥ 8 reads of total
17 coverage of that position. Common mutations in cancer were annotated using SnpSift and
18 COSMIC. Copy number variants in tumor WGS datasets were called using GATK4 CNV to
19 compare them to a panel comprised of the normal-tissue WGS datasets generated in this study.
20 Recurrent copy number variants within polyomavirus-containing tumors or tumors with no virus
21 were determined using GISTIC2 with default parameters. Visualization and variant calling for
22 BKPyV was performed on alignments against a BKPyV genotype Ib-2 isolate (accession
23 number: AB369087.1).

24

25 *Mutation signature analysis*

1 Mutation signature analysis was conducted using the likely somatic variants passing all the
2 above criteria. Mutational Patterns and Somatic Signatures R packages were used for de novo
3 somatic mutations signature analysis.

4

5 *Data visualization*

6 All graphs were made in the R statistical environment (4.0.3) using the package ggplot2 or using
7 Graphpad Prism.

8

9 *Availability of data and materials*

10 All refseqs for human papillomaviruses were downloaded from PaVE and refseqs for human
11 polyomaviruses were downloaded from NCBI as of November 2018. All data generated in this
12 study will be available from dbGaP under accession #####. Viral contigs from this study will be
13 deposited in GenBank under accessions #####. Code used in this manuscript are available
14 from www.github.com/gstarrett.

15

16

17 **Funding**

18 This work was funded by the NIH Intramural Research Program.

19

20 **Acknowledgments**

21 We would like to thank the CCR Genomics Core and CCR Sequencing Facility for their
22 assistance with sequencing. This work utilized the computational resources of the NIH HPC
23 Biowulf cluster (<http://hpc.nih.gov>). We would also like to thank the members of the Laboratory
24 of Cellular Oncology for their useful discussion and insights.

25 We would like to the staff at the Scientific Registry of Transplant Recipients and participating
26 cancer registries who assisted with collection of the data and registry linkages.

1 Disclaimer: The views expressed in this article are those of the authors and should not be
2 interpreted to reflect the views or policies of the National Cancer Institute, the Health Resources
3 and Services Administration, the Scientific Registry of Transplant Recipients, the cancer
4 registries, or their contractors.

5
6 **References**

- 7 1. de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer
8 attributable to infections in 2018: a worldwide incidence analysis. *The Lancet Global Health*.
9 2020;8(2):e180-e90.
- 10 2. Zapatka M, Borozan I, Brewer DS, Iskar M, Grundhoff A, Alawi M, et al. The landscape of
11 viral associations in human cancers. *Nat Genet*. 2020;52(3):320-30.
- 12 3. Cantalupo PG, Katz JP, Pipas JM. Viral sequences in human cancer. *Virology*.
13 2018;513:208-16.
- 14 4. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, et al. Identification of
15 herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. *Science (New York, NY)*.
16 1994;266(5192):1865-9.
- 17 5. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human
18 Merkel cell carcinoma. *Science (New York, NY)*. 2008;319(5866):1096-100.
- 19 6. D'Arcy ME, Castenson D, Lynch CF, Kahn AR, Morton LM, Shiels MS, et al. Risk of rare
20 cancers among solid organ transplant recipients. *J Natl Cancer Inst*. 2020.
- 21 7. Graham SV. The human papillomavirus replication cycle, and its links to cancer
22 progression: a comprehensive review. *Clin Sci (Lond)*. 2017;131(17):2201-21.
- 23 8. Rosty C, Sheffer M, Tsafrir D, Stransky N, Tsafrir I, Peter M, et al. Identification of a
24 proliferation gene cluster associated with HPV E6/E7 expression level and viral DNA load in
25 invasive cervical carcinoma. *Oncogene*. 2005;24(47):7094-104.
- 26 9. Crook T, Tidy JA, Vousden KH. Degradation of p53 can be targeted by HPV E6 sequences
27 distinct from those required. *Cell*. 1991;67:547-56.
- 28 10. Mirabello L, Yeager M, Yu K, Clifford GM, Xiao Y, Zhu B, et al. HPV16 E7 Genetic
29 Conservation Is Critical to Carcinogenesis. *Cell*. 2017;170(6):1164-74.e6.
- 30 11. Decaprio Ja. Human papillomavirus type 16 E7 perturbs DREAM to promote cellular
31 proliferation and mitotic gene expression. *Oncogene*. 2013;33(September):1-3.
- 32 12. Barbosa MS, Edmonds C, Fisher C, Schiller JT, Lowy DR, Vousden KH. The region of the
33 HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate
34 domains for Rb binding and casein kinase II phosphorylation. *The EMBO journal*. 1990;9(1):153-
35 60.
- 36 13. Moens U, Macdonald A. Effect of the Large and Small T-Antigens of Human
37 Polyomaviruses on Signaling Pathways. *Int J Mol Sci*. 2019;20(16).
- 38 14. Shuda M, Feng H, Kwun HJ, Rosen ST, Gjoerup O, Moore PS, et al. T antigen mutations
39 are a human tumor-specific signature for Merkel cell polyomavirus. *Proceedings of the National
40 Academy of Sciences of the United States of America*. 2008;105:16272-7.

- 1 15. Kassem A, Schöpflin A, Diaz C, Weyers W, Stickeler E, Werner M, et al. Frequent
2 detection of merkel cell polyomavirus in human merkel cell carcinomas and identification of a
3 unique deletion in the VP1 gene. *Cancer Research*. 2008;68(13):5009-13.
- 4 16. Gupta G, Kuppachi S, Kalil RS, Buck CB, Lynch CF, Engels EA. Treatment for presumed BK
5 polyomavirus nephropathy and risk of urinary tract cancers among kidney transplant recipients
6 in the United States. *Am J Transplant*. 2018;18(1):245-52.
- 7 17. Vajdic CM, van Leeuwen MT. Cancer incidence and risk factors after solid organ
8 transplantation. *Int J Cancer*. 2009;125(8):1747-54.
- 9 18. Li YJ, Wu HH, Chen CH, Wang HH, Chiang YJ, Hsu HH, et al. High Incidence and Early
10 Onset of Urinary Tract Cancers in Patients with BK Polyomavirus Associated Nephropathy.
11 *Viruses*. 2021;13(3).
- 12 19. Papadimitriou JC, Randhawa P, Rinaldo CH, Drachenberg CB, Alexiev B, Hirsch HH. BK
13 Polyomavirus Infection and Renourinary Tumorigenesis. *Am J Transplant*. 2016;16(2):398-406.
- 14 20. Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al.
15 Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. *Cell*.
16 2017;171(3):540-56 e25.
- 17 21. Burns MB, Temiz Na, Harris RS. Evidence for APOBEC3B mutagenesis in multiple human
18 cancers. *Nature genetics*. 2013;45(9):977-83.
- 19 22. Roberts Sa, Lawrence MS, Klimczak LJ, Grimm Sa, Fargo D, Stojanov P, et al. An APOBEC
20 cytidine deaminase mutagenesis pattern is widespread in human cancers. *Nature genetics*.
21 2013;45(9):970-6.
- 22 23. Poulain F, Lejeune N, Willemart K, Gillet NA. Footprint of the host restriction factors
23 APOBEC3 on the genome of human viruses. *PLoS Pathog*. 2020;16(8):e1008718.
- 24 24. Swanton C, McGranahan N, Starrett GJ, Harris RS. APOBEC enzymes: Mutagenic fuel for
25 cancer evolution and heterogeneity. *Cancer Discovery*. 2015;5(7):704-12.
- 26 25. Mori S, Takeuchi T, Ishii Y, Yugawa T, Kiyono T, Nishina H, et al. Human papillomavirus
27 16 E6 up-regulates APOBEC3B via the TEAD transcription factor. *Journal of Virology*.
28 2017;JVI.02413-16.
- 29 26. Warren CJ, Westrich JA, Doorslaer KV, Pyeon D. Roles of APOBEC3A and APOBEC3B in
30 Human Papillomavirus Infection and Disease Progression. *Viruses*. 2017;9(8).
- 31 27. Ahasan MM, Wakae K, Wang Z, Kitamura K, Liu G, Koura M, et al. APOBEC3A and 3C
32 decrease human papillomavirus 16 pseudovirion infectivity. *Biochemical and biophysical
33 research communications*. 2015;457(3):295-9.
- 34 28. Warren CJ, Xu T, Guo K, Griffin LM, Westrich Ja, Lee D, et al. APOBEC3A functions as a
35 restriction factor of human papillomavirus. *Journal of virology*. 2014;89(1):688-702.
- 36 29. Vieira VC, Leonard B, White EA, Starrett GJ, Temiz Na, Lorenz LD, et al. Human
37 papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase
38 APOBEC3B. *mBio*. 2014;5(6):1-8.
- 39 30. Starrett GJ, Serebrenik AA, Roelofs PA, McCann JL, Verhalen B, Jarvis MC, et al.
40 Polyomavirus T Antigen Induces APOBEC3B Expression Using an LXCXE-Dependent and TP53-
41 Independent Mechanism. *MBio*. 2019;10(1).
- 42 31. Peretti A, Geoghegan EM, Pastrana DV, Smola S, Feld P, Sauter M, et al. Characterization
43 of BK Polyomaviruses from Kidney Transplant Recipients Suggests a Role for APOBEC3 in Driving
44 In-Host Virus Evolution. *Cell Host Microbe*. 2018;23(5):628-35 e7.

- 1 32. Verhalen B, Starrett GJ, Harris RS, Jiang M. Functional Upregulation of the DNA Cytosine
2 Deaminase APOBEC3B by Polyomaviruses. *Journal of virology*. 2016;90(14):6379-86.
- 3 33. Starrett GJ, Thakuria M, Chen T, Marcelus C, Cheng J, Nomburg J, et al. Clinical and
4 molecular characterization of virus-positive and virus-negative Merkel cell carcinoma. *Genome*
5 *Med*. 2020;12(1):30.
- 6 34. Starrett GJ, Marcelus C, Cantalupo PG, Katz JP, Cheng J, Akagi K, et al. Merkel Cell
7 Polyomavirus Exhibits Dominant Control of the Tumor Genome and Transcriptome in Virus-
8 Associated Merkel Cell Carcinoma. *MBio*. 2017;8(1).
- 9 35. Akagi K, Li J, Broutian TR, Padilla-Nash H, Xiao W, Jiang B, et al. Genome-wide analysis of
10 HPV integration in human cancers reveals recurrent, focal genomic instability. *Genome*
11 *research*. 2014;24(2):185-99.
- 12 36. Tisza MJ, Pastrana DV, Welch NL, Stewart B, Peretti A, Starrett GJ, et al. Discovery of
13 several thousand highly diverse circular DNA viruses. *Elife*. 2020;9.
- 14 37. de Kanter JK, Peci F, Bertrums E, Rosendahl Huber A, van Leeuwen A, van Roosmalen
15 MJ, et al. Antiviral treatment causes a unique mutational signature in cancers of transplantation
16 recipients. *Cell Stem Cell*. 2021;28(10):1726-39 e6.
- 17 38. Nassar AH, Umeton R, Kim J, Lundgren K, Harshman LC, Van Allen EM, et al. Mutational
18 analysis of 472 urothelial carcinoma across grades and anatomic sites. *Clin Cancer Res*. 2018.
- 19 39. Su X, Lu X, Bazai SK, Comperat E, Mouawad R, Yao H, et al. Comprehensive integrative
20 profiling of upper tract urothelial carcinomas. *Genome Biol*. 2021;22(1):7.
- 21 40. Cancer T, Atlas G, Weinstein JN, Akbani R, Broom BM, Wang W, et al. Comprehensive
22 molecular characterization of urothelial bladder carcinoma. *Nature*. 2014;507(7492):315-22.
- 23 41. Llewellyn MA, Gordon NS, Abbotts B, James ND, Zeegers MP, Cheng KK, et al. Defining
24 the frequency of human papillomavirus and polyomavirus infection in urothelial bladder
25 tumours. *Sci Rep*. 2018;8(1):11290.
- 26 42. Schneidewind L, Neumann T, Plis A, Bruckmann S, Keiser M, Kruger W, et al. Novel 3D
27 organotypic urothelial cell culture model for identification of new therapeutic approaches in
28 urological infections. *J Clin Virol*. 2020;124:104283.
- 29 43. Nguyen DTT, Richter D, Michel G, Mitschka S, Kolanus W, Cuevas E, et al. The ubiquitin
30 ligase LIN41/TRIM71 targets p53 to antagonize cell death and differentiation pathways during
31 stem cell differentiation. *Cell Death Differ*. 2017;24(6):1063-78.
- 32 44. Czech-Sioli M, Gunther T, Therre M, Spohn M, Indenbirken D, Theiss J, et al. High-
33 resolution analysis of Merkel Cell Polyomavirus in Merkel Cell Carcinoma reveals distinct
34 integration patterns and suggests NHEJ and MMBIR as underlying mechanisms. *PLoS Pathog*.
35 2020;16(8):e1008562.
- 36 45. Warburton A, Redmond CJ, Dooley KE, Fu H, Gillison ML, Akagi K, et al. HPV integration
37 hijacks and multimerizes a cellular enhancer to generate a viral-cellular super-enhancer that
38 drives high viral oncogene expression. *PLoS Genet*. 2018;14(1):e1007179.
- 39 46. Dooley KE, Warburton A, McBride AA. Tandemly Integrated HPV16 Can Form a Brd4-
40 Dependent Super- Enhancer-Like Element That Drives Transcription of Viral Oncogenes.
41 2016;7(5):2-11.
- 42 47. Jeannot E, Harle A, Holmes A, Sastre-Garau X. Nuclear factor I X is a recurrent target for
43 HPV16 insertions in anal carcinomas. *Genes Chromosomes Cancer*. 2018;57(12):638-44.

- 1 48. Wallez Y, Riedl SJ, Pasquale EB. Association of the breast cancer antiestrogen resistance
2 protein 1 (BCAR1) and BCAR3 scaffolding proteins in cell signaling and antiestrogen resistance. *J*
3 *Biol Chem*. 2014;289(15):10431-44.
- 4 49. Wilson AL, Schrecengost RS, Guerrero MS, Thomas KS, Bouton AH. Breast cancer
5 antiestrogen resistance 3 (BCAR3) promotes cell motility by regulating actin cytoskeletal and
6 adhesion remodeling in invasive breast cancer cells. *PLoS One*. 2013;8(6):e65678.
- 7 50. Alexiev BA, Randhawa P, Vazquez Martul E, Zeng G, Luo C, Ramos E, et al. BK virus-
8 associated urinary bladder carcinoma in transplant recipients: report of 2 cases, review of the
9 literature, and proposed pathogenetic model. *Hum Pathol*. 2013;44(5):908-17.
- 10 51. Sirohi D, Vaske C, Sanborn Z, Smith SC, Don MD, Lindsey KG, et al. Polyoma virus-
11 associated carcinomas of the urologic tract: a clinicopathologic and molecular study. *Mod*
12 *Pathol*. 2018.
- 13 52. Kenan DJ, Mieczkowski PA, Burger-Calderon R, Singh HK, Nিকেleit V. The oncogenic
14 potential of BK-polyomavirus is linked to viral integration into the human genome. *J Pathol*.
15 2015;237(3):379-89.
- 16 53. Kenan DJ, Mieczkowski PA, Latulippe E, Cote I, Singh HK, Nিকেleit V. BK Polyomavirus
17 Genomic Integration and Large T Antigen Expression: Evolving Paradigms in Human
18 Oncogenesis. *Am J Transplant*. 2017;17(6):1674-80.
- 19 54. Nিকেleit V, Singh HK, Kenan DJ, Mieczkowski PA. The two-faced nature of BK
20 polyomavirus: lytic infection or non-lytic large-T-positive carcinoma. *J Pathol*. 2018.
- 21 55. Caller LG, Davies CTR, Antrobus R, Lehner PJ, Weekes MP, Crump CM. Temporal
22 Proteomic Analysis of BK Polyomavirus Infection Reveals Virus-Induced G2 Arrest and Highly
23 Effective Evasion of Innate Immune Sensing. *J Virol*. 2019;93(16).
- 24 56. Harris KF, Christensen JB, Imperiale MJ. BK virus large T antigen: interactions with the
25 retinoblastoma family of tumor suppressor proteins and effects on cellular growth control.
26 *Journal of virology*. 1996;70(4):2378-86.
- 27 57. Fischer M, Muller GA. Cell cycle transcription control: DREAM/MuvB and RB-E2F
28 complexes. *Crit Rev Biochem Mol Biol*. 2017;52(6):638-62.
- 29 58. Sadasivam S, Duan S, DeCaprio JA. The MuvB complex sequentially recruits B-Myb and
30 FoxM1 to promote mitotic gene expression. *Genes Dev*. 2012;26(5):474-89.
- 31 59. Schade AE, Oser MG, Nicholson HE, DeCaprio JA. Cyclin D-CDK4 relieves cooperative
32 repression of proliferation and cell cycle gene expression by DREAM and RB. *Oncogene*.
33 2019;38(25):4962-76.
- 34 60. Tye S, Ronson GE, Morris JR. A fork in the road: Where homologous recombination and
35 stalled replication fork protection part ways. *Semin Cell Dev Biol*. 2021;113:14-26.
- 36 61. Bianco JN, Bergoglio V, Lin YL, Pillaire MJ, Schmitz AL, Gilhodes J, et al. Overexpression
37 of Claspin and Timeless protects cancer cells from replication stress in a checkpoint-
38 independent manner. *Nat Commun*. 2019;10(1):910.
- 39 62. Guma S, Maglantay R, Lau R, Wiczorek R, Melamed J, Deng FM, et al. Papillary
40 urothelial carcinoma with squamous differentiation in association with human papilloma virus:
41 case report and literature review. *Am J Clin Exp Urol*. 2016;4(1):12-6.
- 42 63. Michel A, Kopp-Schneider A, Zentgraf H, Gruber AD, de Villiers EM. E6/E7 expression of
43 human papillomavirus type 20 (HPV-20) and HPV-27 influences proliferation and differentiation
44 of the skin in UV-irradiated SKH-hr1 transgenic mice. *J Virol*. 2006;80(22):11153-64.

- 1 64. Viarisio D, Muller-Decker K, Accardi R, Robitaille A, Durst M, Beer K, et al. Beta HPV38
2 oncoproteins act with a hit-and-run mechanism in ultraviolet radiation-induced skin
3 carcinogenesis in mice. *PLoS Pathog.* 2018;14(1):e1006783.
- 4 65. Dell'Oste V, Azzimonti B, De Andrea M, Mondini M, Zavattaro E, Leigheb G, et al. High
5 beta-HPV DNA loads and strong seroreactivity are present in epidermodysplasia verruciformis. *J*
6 *Invest Dermatol.* 2009;129(4):1026-34.
- 7 66. Viarisio D, Muller-Decker K, Zanna P, Kloz U, Aengeneyndt B, Accardi R, et al. Novel ss-
8 HPV49 transgenic mouse model of upper digestive tract cancer 2016.
- 9 67. Solis M, Velay A, Porcher R, Domingo-Calap P, Soulier E, Joly M, et al. Neutralizing
10 Antibody-Mediated Response and Risk of BK Virus-Associated Nephropathy. *J Am Soc Nephrol.*
11 2018;29(1):326-34.
- 12 68. Querido S, Fernandes I, Weigert A, Casimiro S, Albuquerque C, Ramos S, et al. High-
13 grade urothelial carcinoma in a kidney transplant recipient after JC virus nephropathy: The first
14 evidence of JC virus as a potential oncovirus in bladder cancer. *Am J Transplant.*
15 2020;20(4):1188-91.
- 16 69. Serebrenik AA, Starrett GJ, Leenen S, Jarvis MC, Shaban NM, Salamango DJ, et al. The
17 deaminase APOBEC3B triggers the death of cells lacking uracil DNA glycosylase. *Proc Natl Acad*
18 *Sci U S A.* 2019;116(44):22158-63.
- 19 70. Chen Z, Wen W, Bao J, Kuhs KL, Cai Q, Long J, et al. Integrative genomic analyses of
20 APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and
21 immunogenicity in multiple cancer types. *BMC Med Genomics.* 2019;12(1):131.
- 22 71. Meier RPH, Muller YD, Dietrich PY, Tille JC, Nikolaev S, Sartori A, et al. Immunologic
23 Clearance of a BK Virus-associated Metastatic Renal Allograft Carcinoma. *Transplantation.*
24 2021;105(2):423-9.
- 25 72. Cuenca AG, Rosales I, Lee RJ, Wu CL, Colvin R, Feldman AS, et al. Resolution of a High
26 Grade and Metastatic BK Polyomavirus-Associated Urothelial Cell Carcinoma Following Radical
27 Allograft Nephroureterectomy and Immune Checkpoint Treatment: A Case Report. *Transplant*
28 *Proc.* 2020.
- 29 73. Fu F, Deng W, Yu S, Liu Y, Yu L, Liu R, et al. Occurrence and regression of BK
30 polyomavirus associated carcinoma: a clinical and next-generation sequencing study. *Clin Sci*
31 *(Lond).* 2018;132(16):1753-63.
- 32 74. Baker SC, Mason AS, Slip RG, Skinner KT, Macdonald A, Masood O, et al. Induction of
33 APOBEC3-mediated genomic damage in urothelium implicates BK polyomavirus (BKPyV) as a
34 hit-and-run driver for bladder cancer. *Oncogene.* 2022;41(15):2139-51.
- 35 75. Jin Y, Zhou Y, Deng W, Wang Y, Lee RJ, Liu Y, et al. Genome-wide profiling of BK
36 polyomavirus integration in bladder cancer of kidney transplant recipients reveals mechanisms
37 of the integration at the nucleotide level. *Oncogene.* 2021;40(1):46-54.
- 38 76. Wang Y, Liu Y, Deng W, Fu F, Yan S, Yang H, et al. Viral integration in BK polyomavirus-
39 associated urothelial carcinoma in renal transplant recipients: multistage carcinogenesis
40 revealed by next-generation virome capture sequencing. *Oncogene.* 2020.
- 41 77. De Vlamincck I, Khush KK, Strehl C, Kohli B, Luikart H, Neff NF, et al. Temporal response of
42 the human virome to immunosuppression and antiviral therapy. *Cell.* 2013;155(5):1178-87.

- 1 78. Blatter JA, Sweet SC, Conrad C, Danziger-Isakov LA, Faro A, Goldfarb SB, et al.
2 Anellovirus loads are associated with outcomes in pediatric lung transplantation. *Pediatr*
3 *Transplant*. 2018;22(1).
- 4 79. Warren CJ, Van Doorslaer K, Pandey A, Espinosa JM, Pyeon D. Role of the host
5 restriction factor APOBEC3 on papillomavirus evolution. *Virus Evolution*. 2015;1(1):vev015-vev.
- 6 80. Robbe P, Popitsch N, Knight SJL, Antoniou P, Becq J, He M, et al. Clinical whole-genome
7 sequencing from routine formalin-fixed, paraffin-embedded specimens: pilot study for the
8 100,000 Genomes Project. *Genet Med*. 2018;20(10):1196-205.
- 9 81. Zhang J, Fujimoto J, Wedge DC, Song X, Seth S, Chow CW, et al. Intratumor
10 heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing.
11 *Science*. 2014;346(6206):256-9.
- 12 82. Poon SL, Huang MN, Choo Y, McPherson JR, Yu W, Heng HL, et al. Mutation signatures
13 implicate aristolochic acid in bladder cancer development. *Genome Med*. 2015;7(1):38-.
- 14 83. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: Ultrafast
15 universal RNA-seq aligner. *Bioinformatics*. 2013;29(1):15-21.
- 16 84. Van Doorslaer K, Li Z, Xirasagar S, Maes P, Kaminsky D, Liou D, et al. The Papillomavirus
17 Episteme: a major update to the papillomavirus sequence database. *Nucleic Acids Res*.
18 2017;45(D1):D499-D506.
- 19 85. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. *Nature methods*.
20 2012;9(4):357-9.
- 21 86. Li D, Liu CM, Luo R, Sadakane K, Lam TW. MEGAHIT: an ultra-fast single-node solution
22 for large and complex metagenomics assembly via succinct de Bruijn graph. *Bioinformatics*.
23 2015;31(10):1674-6.
- 24 87. Bushmanova E, Antipov D, Lapidus A, Prjibelski AD. rnaSPAdes: a de novo transcriptome
25 assembler and its application to RNA-Seq data. *Gigascience*. 2019;8(9).
- 26 88. Tisza MJ, Belford AK, Dominguez-Huerta G, Bolduc B, Buck CB. Cenote-Taker 2
27 democratizes virus discovery and sequence annotation. *Virus Evol*. 2021;7(1):veaa100.
- 28 89. Marti-Carreras J, Mineeva-Sangwo O, Topalis D, Snoeck R, Andrei G, Maes P. BKTyper:
29 Free Online Tool for Polyoma BK Virus VP1 and NCCR Typing. *Viruses*. 2020;12(8).
- 30 90. Starrett GJ. Oncovirus tools. GitHub2020.
- 31 91. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, et al. SPAdes: a
32 new genome assembly algorithm and its applications to single-cell sequencing. *J Comput Biol*.
33 2012;19(5):455-77.
- 34 92. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for
35 RNA-seq data with DESeq2. *Genome Biology*. 2014;15(550):1-21.
- 36 93. Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al. Enrichr: a
37 comprehensive gene set enrichment analysis web server 2016 update. *Nucleic Acids Res*.
38 2016;44(W1):W90-7.
- 39 94. Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, et al. Enrichr: interactive and
40 collaborative HTML5 gene list enrichment analysis tool. *BMC Bioinformatics*. 2013;14:128.
- 41 95. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, et al. VarScan 2: somatic
42 mutation and copy number alteration discovery in cancer by exome sequencing. *Genome Res*.
43 2012;22(3):568-76.

1 96. Wilm A, Aw PP, Bertrand D, Yeo GH, Ong SH, Wong CH, et al. LoFreq: a sequence-quality
2 aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-
3 throughput sequencing datasets. *Nucleic Acids Res.* 2012;40(22):11189-201.

4 97. Fang LT, Afshar PT, Chhibber A, Mohiyuddin M, Fan Y, Mu JC, et al. An ensemble
5 approach to accurately detect somatic mutations using SomaticSeq. *Genome Biol.* 2015;16:197.

6

7

8 **Figure Legends**

9 **Figure 1. Detection of viral sequences.** A. Primary tumors. B. Metastatic tumors. C. Normal
10 tissues. Viral species are shown on the rows, and each case in the cohort (represented with a
11 TBC number) is a column. Circle size represents the breadth or fraction of the viral genome
12 covered, and color represents the average depth of coverage of the viral k-mers with all
13 coverages over 100 binned together. Specimens without sequencing data have a gray
14 background.

15

16 **Figure 2. Virus diversity and integration.** A. Phylogenetic tree of BKPyV LTA_g sequences
17 detected in tumors (red) and reference genotypes. B. Sites of BKPyV integration into host
18 chromosomes are indicated with case numbers. Two separate sections from separate FFPE
19 blocks of the primary tumor were sequenced for case TBC03 (samples TBC03.1 and TBC03.2).
20 Two separate sections were also sequenced for case TBC09, but an integration site was only
21 detected in sample TBC09.1. Integration sites were also detected in normal tissue sample
22 TBC09N. Black and gray bars indicate cytogenetic bands; red bars indicate centromeres. C.
23 Coverage plot of focal amplifications adjacent to BKPyV integration sites in cases TBC03,
24 TBC04, and TBC08. BKPyV integration junctions are indicated by a black arrow. Colored
25 numbers in the body of the graph indicate coverage depth.

26

27 **Figure 3. BKPyV DNA, RNA and LTA_g detection in tumors.** A. Barplots showing the
28 abundance of BKPyV DNA and RNA reads standardized to human reads B. Barplots of

1 histologically estimated percent tumor purity and IHC-positivity for polyomavirus LTAg
2 expression. C. Representative coverage plots for BKPyV DNA (gray) and RNA (red) in BKPyV-
3 positive tumors. Relative copy numbers are indicated by colored boxes and highlight the
4 borders of duplications and deletions in the viral genome. D. Selected images for LTAg IHC
5 highlighting positive staining for BKPyV-positive tumors with scale bars representing 500
6 microns.

7
8 **Figure 4. Differential gene expression in BKPyV-positive tumors.** A. Volcano plot of
9 differential gene expression between BKPyV-positive and virus-negative tumors. Significantly
10 differentially expressed genes (q -value < 0.05) with a fold change greater than 2 are in red,
11 genes with a fold change less than 2 are in pink. Non-significant genes are in gray. B. Variance
12 stabilized counts for APOBEC3B from DESeq grouped by normal tissues, virus-negative
13 tumors, and BKPyV-positive tumors showing significantly increased expression in BKPyV-
14 positive tumors. C. Heatmap of Z-scores of significantly differentially expressed genes and
15 genes relevant to bladder cancer grouped by gene ontology. High expression is red, low
16 expression is blue. Tumors are colored by likely etiology: BKPyV-positive, red; JCPyV-positive,
17 goldenrod; HR-HPV-positive, blue; TTV-positive, green; aristolochic acid, purple; other, black.
18 Tumors with evidence of integration are in italics.

19
20 **Figure 5. Copy number variants.** Frequency plots for large copy number variants in A. BKPyV-
21 positive and C. virus-negative tumors. Frequency of gains/amplifications are shown in red;
22 losses/deletions are shown in blue. Sample level copy number variant spectra for B. BKPyV-
23 positive and D. virus-negative tumors. Complete deletions are in dark blue and high copy
24 amplifications are in red.

25

1 **Figure 6. Somatic point mutations and mutation signature analysis.** A. Tumor mutation
2 burden (TMB, non-synonymous mutations per million bases) for each tumor in this study. Bars
3 are colored by viral positivity (red, BKPyV; green, TTV; blue, HR-HPV; goldenrod, JCPyV) or
4 etiologic agent (aristolochic acid, purple). B. Barplots of the contribution each trinucleotide
5 substitution for the four deconvoluted signatures with the likely mutation process indicated. C.
6 Proportion of each deconvoluted signature that contributes to each sample with virus status
7 indicated by colored circles (red, BKPyV; green, TTV; blue, HR-HPV; goldenrod, JCPyV). D.
8 Number of unique and common trunk mutations in primary-metastatic tumor pairs and tumors
9 with multi-region sequencing. For TBC03, TBC09, and TBC28, branches 1 and 2 refer to two
10 separate areas of the same tumor. For TBC06 and TBC34, branches P and M refer to the
11 primary tumor and metastasis, respectively. E. Oncoprint for the top mutated genes in bladder
12 cancers of transplant patients. Tumors IDs are colored by likely etiology: BKPyV-positive, red;
13 JCPyV-positive, goldenrod; HR-HPV-positive, blue; TTV-positive, green; aristolochic acid,
14 purple; other, black.
15

1 **Tables:**

2 **Table 1. Characteristics of post-transplant bladder cancer cases (N=43)**

3

Characteristic	Statistic	
Sex, N (%)		
Female	13	(30)
Male	30	(70)
Age in years at diagnosis, median (IQR)	65	(60, 71)
Transplanted organ, N (%)		
Kidney	24	(56)
Liver	4	(9)
Heart and/or lung	14	(33)
Pancreas	1	(2)
Race, N (%)		
Non-Hispanic White	30	(70)
Asian/Pacific Islander	7	(16)
Hispanic	5	(12)
Years from transplant to diagnosis, median (IQR)	5.8	(3, 7)
Non-Hispanic White	6.0	(4,8)
Asian/Pacific Islander	4.7	(3,8)
Hispanic	1.1	(1,8)
Summary stage, N (%)		
In situ	12	(28)
Localized	19	(46)
Regional	7	(14)
Distant	5	(12)
Grade, N (%)		
Low	20	(47)
High	22	(51)
Papillary urothelial neoplasm of low malignant potential	1	(2)

4

5

1 **Table 2. BKPyV integrations sites and microhomology**

ID	Human sequence match	Virus sequence match	Maximum MH length	MH Sequence	Chromosome	Position	Nearest Gene (Symbol)	Nearest Gene (Ensembl ID)	Distance to Nearest Gene	Nearest RE	Distance to Nearest RE
TBC02	CATCATGATGATGGG	GATGGGCAGCCTA	5	ATGGG	chr2	120378301	INHBB	ENSG00000163083	-26499	MIRb	-45
TBC02	CTCCTGCTCATGAA	CATGAAGGTTAAGCATGCTA	5	ATGAA	chr4	145732354	C4orf51	ENSG00000237136	0	AluSq2	-474
TBC02	ACCATTTAATCCCAA	AGTGGAAATTAC	2	AC	chr4	145732375	C4orf51	ENSG00000237136	0	AluSq2	-495
TBC03.1	GCCTTTCTTGAGACTGGGT	ATTTTCATTTCTACTGGGTCAGGA	0	No overlap	chr1	93693546	BCAR3	ENSG00000137936	0	MIRb	377
TBC03.1	TCTGTTTCTTATTT CAGAA	GGGTTCTCCTGTTTATAAGGTC	2	TC	chr1	93693570	BCAR3	ENSG00000137936	0	MIRb	353
TBC03.1	AGAGCCTTGGTGGTGG	GGTGGCAAACAGTGCAG	5	GGTGG	chr1	93693890	BCAR3	ENSG00000137936	0	MIRb	33
TBC03.1	GATACTTTTTAGACATGC	AACCATGACCTCAGGAAGGA	4	CATG	chr1	93694075	BCAR3	ENSG00000137936	0	MIRb	0
TBC03.1	CCTCAAAGCCACCCTACTCC	TTTCATGAGCCCCAAA	5	CCAAA	chr1	93694843	BCAR3	ENSG00000137936	0	MER5A	-92
TBC03.1	CAATTTTTTTTTTTT	TTTTTTTATTTGTAAGGGTG	7	TTTTTTT	chr12	50449935	LARP4	ENSG00000161813	0	AluSc	0
TBC03.1	TGCAAGGTGCTTCATGTAT	AGGGGGCTTAAAGGATGCA	4	TGCA	chr14	95764390		ENSG00000257275	-6735	MIRb	0
TBC03.1	TAGCAAAAAAAAAAAGG	AAAAAAAAAGGCCACAG	11	AAAAAAAAAGG	chr20	8525269	PLCB1	ENSG00000182621	0	MIRmSINE1	154
TBC03.1	CAATTTGGAAAAAAT	ATGCAAGGGCAGTGCACA	2	AT	chr3	73059264	PPP4R2	ENSG00000163605	0	MER103C	69
TBC03.1	TAAAAAGTGTCA	AAGTGTCAATAGAGAAAAA	8	AAGTGTCA	chr4	142307350	INPP4B	ENSG00000109452	0	L2a	0
TBC03.1	TCACACAATTT-TACTCCTCT	ACACTTTTTACACTCCTCTA	8	ACTCCTCT	chr8	140923993	PTK2	ENSG00000169398	0	L2a	0
TBC03.2	GTTGAGTTGGAGCA	CATCTAAATCTCTCAAAT	2	CA	chr1	93693160	BCAR3	ENSG00000137936	0	MER5A1	-10
TBC03.2	ACCCAGTCCACAAGAAAGGC	CCAGTAGAAATGAAAAT	0	No overlap	chr1	93693546	BCAR3	ENSG00000137936	0	MIRb	377
TBC03.2	TCTGTTTCTTATTT CAG	GTTCTCCTGTTTATAAGGTC	2	TC	chr1	93693570	BCAR3	ENSG00000137936	0	MIRb	353
TBC04	GAGTGAGTTCATAG	CAACACTGGTGGAG-TGAGTT	4	GAGT	chr3	5202593	EDEM1	ENSG00000134109	0	L2b	-466
TBC06	CAGACATT-AGGA	TGAGGACCTAACCTGT	4	AGGA	chr2	201676427	MPP4	ENSG00000082126	0	MIR1_Amn	0
TBC08	TCCACTTT CAGTACTT	TGCAAAAAATCAAAT	1	T	chr6	148535326	SASH1	ENSG00000111961	0	AluSq	995
TBC09.1	GGGGCGGTAAGTGAAG	ACTAGAAGCTTGTGCT	8	ACTAGAAG	chr17	61340185	BCAS3	ENSG00000141376	0	L2-3_Crp	0
TBC09N	GAGAAAATAGGACTCGG	AAGATTCGCTGAGAAAA	7	GAGAAAA	chr18	8169205	PTPRM	ENSG00000173482	0	MER127	-648
TBC09N	TCCATCCTCCTCTAC	CTCCTCTACATTGT	9	CTCCTCTAC	chr3	34028749	LINC01811	ENSG00000226320	130585	L2b	0
TBC09N	ATGTAATATAAACT	CATGATTTTAAACCAG	0	No overlap	chr3	117678477		ENSG00000239268	0	L2c	0

2

3

4 **Supporting Information Legends**

5

6 **Figure S1. All SV40 LTag staining, BKPyV DNA/RNA coverage, and regulatory region**

7 **structures.** A. Coverage plots for BKPyV DNA (gray) and RNA (red) in BKPyV-positive tumors.

8 B. Selected images for LTag IHC highlighting positive staining for BKPyV-positive tumors with a

9 scale bar representing 500 microns. C. Heatmap of normalized expression (transcripts per

1 million, TPM) of BKPyV genes per tumor. D. Diagrams of BKPyV NCCR structures and
2 rearrangements in tumors. P=Primary tumor, M=metastatic tumor.

3
4 **Figure S2. APOBEC3B germline variant and expression by BKPyV status.** Stabilized
5 counts of APOBEC3B expression divided by tissue type (primary tumor, normal tissue), BKPyV
6 status (BK), and germline variant rs1014971 status.

7
8 **Figure S3. All JCPyV DNA/RNA coverage plots.** Representative coverage plots for JCPyV
9 DNA (gray) and RNA (red) in JCPyV-positive tumors.

10
11 **Figure S4. All HPV DNA/RNA coverage plots.** Representative coverage plots for HPV DNA
12 (gray) and RNA (red) in HPV-positive tumors. Diagrams of open reading frames for each
13 respective type are below the coverage plots.

14
15 **Figure S5. Mutations signature deconvolution.** A. Residual sum of squares and explained
16 variance for 2-10 signatures deconvoluted by SomaticSignatures. B. Barplot of base
17 substitution contributions to each of the four deconvoluted signatures from SomaticSignatures.
18 C. Heatmap of cosine similarities of four signatures deconvoluted by Somatic Signatures versus
19 known Single Base Substitution Signatures (SBS). D. NMF rank survey results for 2-10
20 signature deconvolution by MutationalPatterns. E. Barplot of base substitution contributions to
21 each of the four deconvoluted signatures from MutationalPatterns. F. Heatmap of cosine
22 similarities of four signatures deconvoluted by MutationalPatterns versus known Single Base
23 Substitution Signatures (SBS) with closest matches highlighted in red.

24
25 Table S1: Sequencing metrics

26 Table S2. Reference sequences used in this study


- 1 Table S3. Tumor torque teno virus similarities
- 2 Table S4: BKPyV-positive tumor vs virus-free tumor significantly differentially expressed genes
- 3 Table S5. Non-synonymous point mutations
- 4 Table S6. Copy number variants
- 5

Figure 1

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.


A

Primary Tumors



B

Metastases



C

Normal Tissues








Figure 2**A****B****C**





Figure 3**A****B****C****D**

Figure 4







Figure 5

Figure 6


A




B



D



C



E

